Gastric mucosal perfusion is increased in portal-hypertensive gastropathy, and this may contribute to gastric bleeding from these lesions. Therefore drugs reducing gastric mucosal perfusion may be beneficial in the treatment of overt bleeding from portal-hypertensive gastropathy. In this study gastric mucosal perfusion was assessed in 28 cirrhotic patients with VP is a powerful vasoconstrictor, which reduces blood flow to the entire splanchnic territory. By this mechanism, it can reduce portal pressure and hepato-portal and collateral blood flow. Nonetheless, VP is not without adverse clinical effects namely those derived from vasoconstriction of the systemic territory. Reduced shown that vasoconstriction and reduction ofportal pressure is more marked after i.v. bolus injection rather than continuous infusion, it is recommended that during the early hours of treatment, a bolus administration be given followed by a constant infusion. Actually, the authors of the present paper recently reported that the increased gastric perfusion that patients with liver cirrhosis and PHG demonstrate can be effectively decreased by SOM. The bolus injection caused a more pronounced reduction in gastric perfusion than a constant infusion did, suggesting a dose-related effect. The greatest advantage of this drug seems to be the lack of side effects. Several trials comparing SOM with other active treatments show that SOM is highly effective in the treatment ofvariceal bleeding, and it is truly a safe therapy. Octreotide 
